ReviewAnnual review of medicine2014
Applied pharmacogenomics in cardiovascular medicine.
Review in Annual review of medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Pharmacogenomics and its Role in Cardiovascular Diseases: A Narrative Literature Review.Current cardiology reviews · 2025Review
- Cannabis Pharmacogenomics: A Path to Personalized Medicine.Current issues in molecular biology · 2023Review
- Pharmacogenomics Informs Cardiovascular Pharmacotherapy.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Genetic variants of GRK4 influence circadian rhythm of blood pressure and response to candesartan in hypertensive patients.Clinical and experimental hypertension (New York, N.Y. : 1993) · 2021Article
- Development of a High Throughput Screen for the Identification of Inhibitors of PeptidoglycanAntibiotics (Basel, Switzerland) · 2019Article
- Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine?European heart journal · 2019Review
- Personalised Medicine: The Odyssey from Hope to Practice.Journal of personalized medicine · 2018Review
- Translating Knowledge Into Therapy for Acute Kidney Injury.Seminars in nephrology · 2018Review
- Review
- Noninvasive Prenatal DNA Testing: The Vanguard of Genomic Medicine.Annual review of medicine · 2017Review
- Effects of 0.5% Timolol Maleate Ophthalmic Solution on Heart Rate and Selected Echocardiographic Indices in Apparently Healthy Cats.Journal of veterinary internal medicine · 2016Article
- Use of contemporary genetics in cardiovascular diagnosis.Circulation · 2014Review
- Role of pharmacogenomics in dialysis and transplantation.Current opinion in nephrology and hypertension · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Interindividual heterogeneity in drug response is a central feature of all drug therapies. Studies in individual patients, families, and populations over the past several decades have identified variants in genes encoding drug elimination or drug target pathways that in some cases contribute substantially to variable efficacy and toxicity. Important associations of pharmacogenomics in cardiovascular medicine include clopidogrel and risk for in-stent thrombosis, steady-state warfarin dose, myotoxicity with simvastatin, and certain drug-induced arrhythmias. This review describes methods used to accumulate and validate these findings and points to approaches--now being put in place at some centers--to implementing them in clinical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.